Abstract: The invention relates to DNA sequences, which code for an apoptotic signal transduction protein (Bcl-Rambo) or for polypeptides with a domain of a protein of this type (BHNo domains of Bcl-Rambo), to expression vectors, host cells, genetic products of the aforementioned sequences and antibodies against said genetic products. The invention also relates to an expression and isolation method, to compounds that modulate the apoptotic action, to a method for identifying compounds of this type and to the use of said compounds, or the DNA sequences, or genetic products as medicaments.

Abstract: The invention relates to methods and compositions for the treatment of human or animal disorders associated with pathophysiologically based extracellular Fas ligand titers, as well as methods for determining the prophylactic suitability and quality control of compositions, such as intravenous immunoglobulin mixtures, for use in such methods, and methods of preparing compositions for treating such disorders.

Abstract: The invention relates to DNA sequences, which code for at least one PYD domain, to expression vectors, which contain DNA sequences of this type, to host cells, which are transformed using expression vectors of this type, to purified gene products of said DNA sequences, to antibodies directed against said gene products, and to methods for isolating and/or expressing said gene products. The invention also relates to the use of said DNA sequences or of their gene products for treating inflammations.

Abstract: Novel receptor in the TNF family: TRAIN-receptor.

Abstract: APRIL, a novel members of the tumor necrosis factor family (TNF), modified APRILs, and pharmaceutical compositions comprising them.

Abstract: The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence.

Abstract: A novel receptor in the TNF family is provided: BAFF-R. Chimeric molecules and antibodies to BAFF-R and methods of use thereof are also provided.

Abstract: The invention relates to nucleic acid molecules that include at least one death effector domain, expression vectors the include these nucleic acid molecules, host cells transformed with such vectors, methods for expressing and/or isolating gene products with at least one death effector domain, and purified or isolated gene products or fragments of these gene products that include at least one death effector domain.

Abstract: The use of inhibitors of cysteine aspartate proteins (caspases) for treating diseases or disorders caused by a hyperproliferation of peripheral blood lymphocytes is disclosed. The use of caspase inhibitors for suppressing the immune system is also disclosed.

Abstract: The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.